- The disease
- Acute myeloid leukaemia (AML) is a cancer of the blood and bone marrow in which the body produces abnormal white blood cells that crowd out healthy cells. Patients whose disease returns after initial treatment (relapsed) or does not respond to treatment (refractory) have limited options and generally poor outcomes. This asset is being studied specifically in this hard-to-treat relapsed or refractory (r/r) population.
- What the asset is trying to do
- Bisantrene is a small molecule that was originally investigated as an anthracenedione-class compound, understood to intercalate into DNA and inhibit topoisomerase II, an enzyme cancer cells rely on to replicate their DNA. It is being studied in combination with other chemotherapy agents including fludarabine and clofarabine (per ClinicalTrials.gov NCT04989335). The specific molecular target listed in the company's current filing is not defined in the available data.
- What the trial is measuring, and why it matters
- The lead trial (NCT04989335) is registered as a Phase 2 study with a target enrolment of 29 patients and a primary completion date of 2024-12-01 (per ClinicalTrials.gov NCT04989335). A completed earlier Phase 2 study (NCT03820908) enrolled 10 patients and reached primary completion in May 2020 (per ClinicalTrials.gov NCT03820908). A third study (NCT05456269) was withdrawn before completion (per ClinicalTrials.gov NCT05456269). The specific primary endpoints for NCT04989335 are .
- Efficacy benchmarks in this setting
- In relapsed or refractory AML, approved salvage regimens provide a reference for response rates. For example, the approved combination of venetoclax (a BCL-2 inhibitor) with azacitidine has reported composite complete remission rates in newly diagnosed AML patients ineligible for intensive chemotherapy; r/r-specific benchmarks vary considerably by prior therapy and cytogenetic risk. Gilteritinib, approved for FLT3-mutated r/r AML, achieved an overall response rate of 21% (per DiNardo et al, published in the FDA label and NEJM 2019). Enasidenib, approved for IDH2-mutated r/r AML, reported an overall response rate of approximately 40% in a single-arm study (per Stein et al, Blood 2017, and the FDA prescribing information). Any figures from bisantrene's early-stage trials are not statistically comparable to these approved-therapy results.
- Commercial context
- Multiple agents are approved in the r/r AML setting in the United States and other major markets, including gilteritinib, enasidenib, ivosidenib, and gemtuzumab ozogamicin, among others, each tied to specific molecular subtypes or clinical settings (per FDA approvals). Bisantrene is not currently approved anywhere for AML based on available data. Racura Oncology raised A$34.3 million to advance three oncology trials (per ASX announcement, 16 June 2026). The company's most recent clinical milestone announcement relates to a lung cancer trial called HARNESS-1 (per ASX announcement, 24 June 2026), indicating bisantrene in AML is not the sole pipeline asset. No deal comparables or manufacturing disclosures for bisantrene are present in the available data.